2024-12-12 - Analysis Report
## Eli Lilly and Co. (LLY) Stock Report

**1. Performance Comparison & Outperformance:**

Eli Lilly and Co. (LLY) is a global pharmaceutical company engaged in the research, development, and manufacturing of pharmaceutical products.

LLY's cumulative return is significantly higher than the S&P 500 (VOO).  The difference in cumulative returns as of the last date in the provided data is 463.4%.  This places LLY at the 74th percentile of its historical relative performance compared to the S&P 500, indicating strong historical outperformance.  Note that this relative outperformance is based on historical data and doesn't guarantee future results.

The provided CAGR data shows consistently strong growth, increasing over time.  The consistently positive Alpha values (although reported as 0.0 in the provided data, this likely reflects a rounding issue and should be interpreted as a positive alpha) suggest the stock has outperformed its benchmark, while the Beta values (also reported as 0.0, but again likely rounding) suggests a low correlation to the overall market. This high CAGR despite a relatively low beta indicates the significant outperformance.  The increasing market capitalization (Cap(B)) reflects company growth.

**2. Recent Price Movement:**

* **Closing Price:** $799.58
* **5-Day Moving Average:** $817.07
* **20-Day Moving Average:** $784.68
* **60-Day Moving Average:** $851.46

The price is currently below both the 5-day and 60-day moving averages, suggesting a potential short-term downward trend, but above the 20-day moving average.  The difference between the last market price (798.82) and the closing price is negligible.

**3. Technical Indicators & Expected Return:**

* **RSI (73.99):**  Indicates the stock is in overbought territory, suggesting a potential pullback.
* **PPO (0.99):**  A positive value suggests bullish momentum.
* **20-Day Relative Strength Change (-1.8%):** Shows a recent slight decrease in relative strength.
* **Expected Return (542.5%):** This represents a very high expected return over the long term (2+ years) compared to the S&P 500. This number needs further context on its calculation methodology to be properly interpreted.


**4. Recent Earnings Analysis:**

The provided earnings data reveals some volatility:

* **EPS:**  Fluctuated significantly across quarters, with a notable spike in Q2 2024 (3.29) followed by a decline in Q3 2024 (1.08). There's also an unusual negative EPS in both November 2023 and October 2024 which requires further investigation beyond the provided data.
* **Revenue:** Showed relatively stable growth, reaching a peak in Q2 2024 ($11.30B) and maintaining strong levels in subsequent quarters.
* **Revenue Growth Trends:** There's no clear upward trend; revenue growth is inconsistent, but generally strong.


**5. Financial Information:**

* **Revenue:**  Generally strong and relatively consistent, with a slight dip in Q1 2024.
* **Profit Margin:** Remained remarkably consistent around 80%, demonstrating strong profitability.
* **Equity:** Showed growth overall, but fluctuated from quarter to quarter.
* **ROE:** Experienced significant fluctuations, ranging from negative values to over 20%, indicating variability in the company's profitability relative to shareholder equity.  Further investigation is needed to understand the cause of such fluctuations.

**6. News and Recent Issues:**

This section requires additional information.  The prompt does not provide any news or recent market outlook data.  Analyst opinions and performance highlights are also missing.

**7. Overall Analysis:**

LLY has demonstrated significant historical outperformance compared to the S&P 500, with impressive CAGR and consistently high profit margins.  However, recent price action suggests a potential short-term pullback, indicated by the RSI and moving averages. The companyâ€™s earnings show volatility in EPS, yet consistently high revenue.  The provided expected return is extremely high and needs further clarification on the calculation methodology.  Further investigation is required to understand the causes of fluctuations in ROE and the unusual negative EPS reported in November 2023 and October 2024.  Missing information on recent news, market outlook, and analyst opinions prevents a complete assessment.  A thorough due diligence process involving more comprehensive data is needed before making any investment decisions.


**8. Disclaimer:** This report is for informational purposes only and does not constitute financial advice.  The analysis is based solely on the limited data provided and should not be considered exhaustive.  Conduct your own thorough research before making any investment decisions.
